CRRT Continue Renal Replacement Therapy

Slides:



Advertisements
Similar presentations
IV Administration – Dosage Calculation
Advertisements

Regional Citrate Anticoagulation during CVVH in the
Intravenous Therapy IV Calculation (Math)
Separation Technology in Dialysis
Ramon C. Mora M.D. Year Graduated : 1985
Norma J Maxvold Pediatric Critical Care
IV infusions Calculating volume of fluid delivered over time:
Renal replacement therapy
Renal Replacement Therapy Options for Children
Continuous renal replacement therapy
Continuous Renal Replacement Therapy
Dialysis in the Critically Ill
Continuous Renal Replacement Therapy
renal replacement therapy in the PICU
Pediatric CRRT: Terminology and Physiology
Hemodiafiltration and Hemofiltration
Definition Continuous Renal Replacement Therapy (CRRT)
CRRT Machines Evolution of CRRT and machines Ideal CRRT machine
Lynda and “Abyle” products
Mathematical Aspects of Intravenous Therapy
CVVH vs CVVHD Does it Matter?
Dr Monidipa Banerjee Dr Papiya Khawas
Nutrition Support of the Critically Ill Patient with Organ Failure.
Not necessarily a recipe
Acute Hemodialysis & CRRT in AKI
MANAGEMENT OF CONTINUOUS HEMODIALYSIS
Continuous Renal Replacement Therapy. Why continuous Therapies? Continuous therapies closely mimic the GFR of native kidneys Large amounts of fluid.
Heparin in CRRT Benan Bayrakci, McLean Antitrombin 3 Inactive Thrombin (IIa) V, VIII, XIII, Fibrinogen Inactive Factor Xa Common Pathway Inactive.
Intensive care conference: management of acid-base disorders with CRRT International Society of Nephrology 主講人 : R2 顏介立.
Troubleshooting Issues in CVVH Timothy L. Kudelka RN, BSN Pediatric Dialysis Program C.S. Mott Children’s Hospital University of Michigan.
RENAL REPLACEMENT THERAPY
Lynda and “Abyle” products. Blood pump Moves blood in all the therapies. In CRRT the blood flow is between 0.30 and 450 ml/min. In CRRT the blood flow.
Terminology and Common Issues in Pediatric CRRT John Gardner RN, BSN Nurse Manager Pediatric Nephrology & Transplant DeVos Children’s Hospital Grand Rapids.
Pediatric CRRT: The Prescription
Continuous Renal Replacement Therapy -CRRT
ANTICOAGULATION IN CONTINUOUS RENAL REPLACEMENT THERAPY Dawn M Eding RN BSN CCRN Pediatric Critical Care Helen DeVos Children's Hospital.
The Clinical Guide “A Guide to Implementing Renal Best Practice in Haemodialysis“ Chapter 5: Anticoagulation Team Leader: Angela Henson Co-authors: Franta.
What form of anticoagulation is the “best” Or why is Citrate better then Heparin or Prostacyclin.
Practical Considerations for CRRT Helen Currier RN, BSN, CNN Nancy McAfee RN, BSN, CNN.
Anticoagulation in CRRT
ANTICOAGULATION in CRRT: Heparin vs. Citrate
Tomáš Zaoral1, Michal Hladík1, Jana Zapletalová2 1Pediatric intensive care unit, Department of Pediatrics,Faculty of Medicine, University Hospital Ostrava.
Sustained Low Efficiency Dialysis
Brophy University of Iowa Pediatric CRRT Anticoagulation Patrick Brophy MD Director Pediatric Nephrology University of Iowa- Children’s Hospital PCRRT.
Citrate Anticoagulation
Common Terminology Used and Physiology in CRRT Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital Seattle, WA.
ANTICOAGULATION PCRRT 2008 Orlando Patrick Brophy MD Director Pediatric Nephrology University of Iowa- Children’s Hospital.
Complications of Pediatric CRRT Theresa A. Mottes RN Pediatric Dialysis/Research Nurse C.S. Mott Children’s Hospital University of Michigan.
PCRRT Multi-Center Registry Data Effective April 1, 2002 Multi-Center Pediatric CRRT Registry Stuart L. Goldstein, MD Assistant Professor of Pediatrics.
Proposal of a flow-chart to avoid circuit clotting in prolonged intermittent renal replacement therapy (PIRRT): a monocentric experience 1 Vincenzo Cantaluppi,
PCRRT Tûr'mə-nŏl'ə-jē Helen Currier BSN, RN, CNN Assistant Director, Renal/Pheresis Texas Children’s Hospital Houston, Texas.
Continuous Renal Replacement Therapy Developed by: Critical Care and Hemodialysis Educators, February 2009 King Faisal Specialist Hospital and Research.
Citrate Continuous Renal Replacement Therapy: Which Protocol? Standard Protocol 1 (SP1) Indication: First hours of therapy Effluent dose target:
Continuous Renal Replacement Therapy with Citrate
CONTINUOUS RENAL REPLACEMENT THERAPY
Continuous renal replacement therapy
CRRT Fundamentals Pre- and Post- Test
Plasma Exchange Chan King Chung.
ANTICUAGULANT A.Rahimzadeh.B.sc,M.sc Shahid Beheshty university
Hemodialysis in 20 kg Patient with AKI and Sepsis
CRRT Fundamentals Pre- and Post- Test Answers
OUTCOMES OF REGIONAL CITRATE ANTICOAGULATION (RCA) IN PEDIARTIC CONTINUOUS RENAL REPLACEMENT THERAPY (pCRRT) IN A SINGLE CENTER Issa Alhamoud, Diane Gollhofer,
Andrew Durward St Thomas NHS Foundation Trust Orlando 2017 CRRT IN AKI.
Pediatric CRRT Terminology
Continuous Dialysis Therapies: Core Curriculum 2016
Continuous renal replacement therapy in the critically ill patient
Basics of CRRT: Terminology
SCUF Slow Continuous Ultrafiltration
CRRT dialysis circuit using regional citrate anticoagulation with the Gambro Prisma machine. CRRT dialysis circuit using regional citrate anticoagulation.
RCA in continuous RRT: basic principles
Presentation transcript:

CRRT Continue Renal Replacement Therapy CVVH CVVHD CVVHDF

Indications In critically ill patients with renal failure and hemodynaemic instability For patients in whom continuous removal of volume or toxic substance is desirable ( as in septic shock , AMI , severe GI bleeding ,ARDS or condition with or at risk for cerebral edema ….)

Procedure共同處 Driving force : external pump Circuit : Venovenous Dialysis solutions :一般使用1.5% PD solution Replacement fluid : several types of replacement fluid can be used , depending on patient requirements ,一般使用 pre-dilution 方式.

Anti-coagulation 的方式 STANDARD HEPARIN TYPICAL REGIMEN IN CRRT : Priming of the circuit ( 5000 IU / L ) Initial Heparin Bolus : 5 - 8 IU / kg Infuse Heparin at : 5 to 12 IU / kg / hr ACT on post filter : Adjust heparin rate to keep ACT between 1.5 & 2.0 times

STANDARD HEPARIN ADVANTAGES Easy to perform Useful method Inexpensive DISADVANTAGES Occasional Thrombocytopenia Hemorrhagic Risk with Bleeding patient

LOW MOLECULAR WEIGHT (LMW) HEPARIN TYPICAL REGIMEN IN CRRT : Priming of the circuit : 20 mg in 1 L Maintenance dose : 10 to 40 mg q6 hrs Monitor anti- factor Xa (aXa) units . Adjust between 0.1 and 0.4 µ/ml Different Dosages for LMW heparin

LOW MOLECULAR WEIGHT (LMW) HEPARIN DISADVANTAGES Expensive Special and difficult monitoring With low doses frequent filter clotting ADVANTAGES Decreased Risk of Bleeding

Regional Citrate Anticoagulation TYPICAL REGIMEN : Citrate anticoagulation is always regional Citrate infusion (4%) at 170 ml/hr initially Special Dialysate at 1 liter/hr ( Na+ 117 , K+ 4 , Mg++ 1.5 , Cl- 121.5 , dextrose 0.5- 2.5% , no Ca++ , no base ) CaCL2 (0.75%) by central I.V at 40-60 ml/hr, Maintain ionized Ca++ at 0.96- 1.20 mmol/L

Citrate ADVANTAGES : No Bleeding No Thrombocytopenia Improved Filter Life and Efficacy DISADVANTAGES : Complex for the set up Ca++ monitoring needed Occasional Alkalosis

Heparin- free methos Normal saline flush Used in patients with 1. Severe liver disease 2. Acitve or recent bleeding 3. Heparine-induced thrombocytopenia 4. Post-op patients

Dialysis modalities in the ICU

CVVH配置簡圖 CVVH Continuous Veno-Venous Hemofiltration CVVH 模式下, 置換液流速 P R I S M A CVVH Continuous Veno-Venous Hemofiltration CVVH 模式下, 置換液流速 最高可達4500ml/hr

CVVH order l    Prepare Heparin 2cc + N/S 3cc, then inject 1.6cc into each femoral cath. l  For AK priming: (GAMBRO, Polyarylethersulfone, 6S) *1st N/S 1000cc. *2nd Heparin 2,500U. *3rd N/S 500cc. l     *Prepare Heparin 25,000U + N/S 500cc IVD 10cc/hr with pump to keep aPPT 1.5-2 and adjust as followed: aPPT bolus hold dose(cc/hr) <1.0 2000U - +4 1.0-1.5 - - +2 1.5-2.0 - - - 2.0-2.5 - 30min -2 >2.5 - 60min -4

CVVH order If non-heparin , N/S 200cc q ½ hr to rinse the AK Predilution run 500cc/hr alternately as followed via artery end 1st bottle N/S 500cc + Sinca 1amp 2nd bottle N/S 500cc + 10% MgSO4 4cc 3rd bottle N/S 500cc 4th bottle D5W 500cc + NaHCO3 5amp Warm dialysate to 37C Record I/O and BP q1hr UF target I-O ( ) cc/hr Check BUN,Crea,Na,K,Cl,aPPT q6hr for 1 day & then q8hr. Check Ca,P,Mg qd.

CVVHD配置簡圖 CVVHD Continuous Veno-Venous Hemodialysis P R I S M A

CVVHD order l    Prepare Heparin 2cc + N/S 3cc, then inject 1.6cc into each femoral cath. l  For AK priming: (GAMBRO, Polyarylethersulfone, 6S) *1st N/S 1000cc. *2nd Heparin 2,500U. *3rd N/S 500cc. l     *Prepare Heparin 25,000U + N/S 500cc IVD 10cc/hr with pump to keep aPPT 1.5-2 and adjust as followed: aPPT bolus hold dose(cc/hr) <1.0 2000U - +4 1.0-1.5 - - +2 1.5-2.0 - - - 2.0-2.5 - 30min -2 >2.5 - 60min -4

CVVHD order If non-heparin , N/S 200cc q ½ hr to rinse the AK 1.5% PD solution 500cc/hr run as dailysate Warm dialysate to 37C Record I/O and BP q1hr UF target I-O ( ) cc/hr Check BUN,Crea,Na,K,Cl,aPPT q6hr for 1 day & then q8hr. Check Ca,P,Mg qd.

CVVHDF配置簡圖 P R I S M A CVVHDF Continuous Veno-Venous Hemodiafiltration

CVVHDF order l    Prepare Heparin 2cc + N/S 3cc, then inject 1.6cc into each femoral cath. l  For AK priming: (GAMBRO, Polyarylethersulfone, 6S) *1st N/S 1000cc. *2nd Heparin 2,500U. *3rd N/S 500cc. l     *Prepare Heparin 25,000U + N/S 500cc IVD 10cc/hr with pump to keep aPPT 1.5-2 and adjust as followed: aPPT bolus hold dose(cc/hr) <1.0 2000U - +4 1.0-1.5 - - +2 1.5-2.0 - - - 2.0-2.5 - 30min -2 >2.5 - 60min -4

CVVHDF order If non-heparin , N/S 200cc q ½ hr to rinse the AK Predilution run 500cc/hr alternately as followed via artery end 1st bottle N/S 500cc + Sinca 1amp 2nd bottle N/S 500cc + 10% MgSO4 4cc 3rd bottle N/S 500cc 4th bottle D5W 500cc + NaHCO3 5amp 1.5% PD solution 500cc/hr run as dailysate Warm predilution and dialysate to 37C Record I/O and BP q1hr UF target I-O ( ) cc/hr Check BUN,Crea,Na,K,Cl,aPPT q6hr for 1 day & then q8hr. Check Ca,P,Mg qd.